Key points
- Cash on hand $2.17m, up 56% from prior quarter
- Revenue receipts up 8% to $0.64m, down 20% from prior year
- Appointed SinoPharm as China distributor, received China regulatory approvals
Full summary
Uscom Ltd has released its Q2 FY25 cash flow report, showing cash on hand of $2.17m, up 56% from the prior quarter of $1.39m but down from $3.18m in the prior corresponding period. Operating cash outflow was $0.13m, a decrease from an inflow of $0.05m in the prior corresponding period. Revenue receipts from customers increased 8% to $0.64m from $0.59m in the prior quarter but decreased 20% from $0.81m in the prior corresponding period. Expenditure for the quarter increased, with staff costs of $0.77m up 3% from the prior corresponding period, and advertising and marketing expenses up 5% to $0.24m. During the quarter, the company appointed SinoPharm as its Chinese distributor and received China regulatory approvals for its BP+ and SpiroSonic products, which are expected to boost sales in the second half of the calendar year.
Outlook
The company expects the new Chinese distributor and regulatory approvals to feed into sales in the second half of the calendar year and boost any continued international uncertainties over the remainder of 2025.